The May 2017 issue of the prestigious AACR journal Molecular Cancer Therapeutics (MCT) contains the peer-reviewed publication of NBE-Therapeutics showcasing highly potent next-generation antibody drug conjugates (ADCs) developed by NBE-Therapeutics. This study showcases the  in vitro and in vivo characterization of site-specifically conjugated ADCs based on benchmark mAbs trastuzumab and brentuximab comprising a derivative of the highly potent anthracycline toxin payload PNU-159682.

This publication is freely accessible for download as a PDF at the link: http://mct.aacrjournals.org/content/molcanther/16/5/879.full.pdf